[go: up one dir, main page]

BR112014014605A2 - moléculas de anticorpo de ligação de trombina e usos das mesmas - Google Patents

moléculas de anticorpo de ligação de trombina e usos das mesmas

Info

Publication number
BR112014014605A2
BR112014014605A2 BR112014014605A BR112014014605A BR112014014605A2 BR 112014014605 A2 BR112014014605 A2 BR 112014014605A2 BR 112014014605 A BR112014014605 A BR 112014014605A BR 112014014605 A BR112014014605 A BR 112014014605A BR 112014014605 A2 BR112014014605 A2 BR 112014014605A2
Authority
BR
Brazil
Prior art keywords
antibody molecules
thrombin
binding antibody
thrombin binding
exositis
Prior art date
Application number
BR112014014605A
Other languages
English (en)
Inventor
Andrew Huntington James
Langdown Jonathan
Frasson Roberta
Baglin Trevor
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of BR112014014605A2 publication Critical patent/BR112014014605A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo moléculas de anticorpo de ligação de trombina e usos das mesmas a invenção se refere a anticorpos isolados que reconhecem o epítopo de exosite 1 de trombina e inibem seletivamente trombina sem promover sangramento. essas moléculas de anticorpo podem ser úteis no tratamento e prevenção de trombose, embolismo e outras condições mediadas por trombina.
BR112014014605A 2011-12-14 2012-12-14 moléculas de anticorpo de ligação de trombina e usos das mesmas BR112014014605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112014014605A2 true BR112014014605A2 (pt) 2017-06-13

Family

ID=45560465

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014605A BR112014014605A2 (pt) 2011-12-14 2012-12-14 moléculas de anticorpo de ligação de trombina e usos das mesmas

Country Status (34)

Country Link
US (5) US9518129B2 (pt)
EP (2) EP3275903A1 (pt)
JP (2) JP6216954B2 (pt)
KR (1) KR102114506B1 (pt)
CN (2) CN107936119B (pt)
AU (2) AU2012351858B2 (pt)
BR (1) BR112014014605A2 (pt)
CA (1) CA2856656C (pt)
CO (1) CO7101192A2 (pt)
CY (1) CY1119599T1 (pt)
DK (1) DK2791177T3 (pt)
ES (1) ES2642718T3 (pt)
GB (1) GB201121513D0 (pt)
HK (1) HK1246326A1 (pt)
HR (1) HRP20171775T1 (pt)
HU (1) HUE034793T2 (pt)
IL (1) IL232797B (pt)
LT (1) LT2791177T (pt)
ME (1) ME02901B (pt)
MX (2) MX353281B (pt)
MY (1) MY170980A (pt)
NO (1) NO2791177T3 (pt)
PE (2) PE20190171A1 (pt)
PH (1) PH12014501169A1 (pt)
PL (1) PL2791177T3 (pt)
PT (1) PT2791177T (pt)
RS (1) RS56510B1 (pt)
RU (2) RU2642276C2 (pt)
SG (1) SG11201402560WA (pt)
SI (1) SI2791177T1 (pt)
SM (1) SMT201700580T1 (pt)
UA (1) UA116531C2 (pt)
WO (1) WO2013088164A1 (pt)
ZA (1) ZA201403836B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518128B2 (en) * 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
US20190315886A1 (en) * 2016-02-05 2019-10-17 Jiangsu Hengrui Medicine Co., Ltd. Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
CA2180140A1 (en) * 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO2001000667A2 (en) 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
WO2001007072A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
PL360060A1 (en) * 2000-05-15 2004-09-06 Smithkline Beecham Corporation Antithrombotic agents
WO2002017711A2 (en) 2000-08-31 2002-03-07 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
WO2003003988A2 (en) * 2001-07-06 2003-01-16 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
ME00016B (me) 2005-08-26 2010-06-10 Aptameri koji vezuje trombin sa visokim afininitetom
US20100158890A1 (en) 2006-03-15 2010-06-24 Kenichi Tanaka Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
PL2297207T3 (pl) 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
US20110275701A1 (en) 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
RU2660370C2 (ru) 2011-07-22 2018-07-05 Цсл Беринг Гмбх Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules

Also Published As

Publication number Publication date
JP6705785B2 (ja) 2020-06-03
EP2791177B1 (en) 2017-09-06
AU2012351858B2 (en) 2017-10-05
CA2856656A1 (en) 2013-06-20
AU2017268655B2 (en) 2019-05-09
CA2856656C (en) 2021-01-19
RU2014124985A (ru) 2016-02-10
US9518129B2 (en) 2016-12-13
PE20141706A1 (es) 2014-11-13
HK1202564A1 (en) 2015-10-02
US20140370008A1 (en) 2014-12-18
PT2791177T (pt) 2017-11-29
JP6216954B2 (ja) 2017-10-25
US20190276558A1 (en) 2019-09-12
US10287363B2 (en) 2019-05-14
MX2014007170A (es) 2015-04-17
CY1119599T1 (el) 2018-04-04
LT2791177T (lt) 2017-11-27
UA116531C2 (uk) 2018-04-10
HK1246326A1 (en) 2018-09-07
RU2017144629A3 (pt) 2021-04-05
US20170066842A1 (en) 2017-03-09
HUE034793T2 (en) 2018-02-28
EP3275903A1 (en) 2018-01-31
HRP20171775T1 (hr) 2017-12-29
CO7101192A2 (es) 2014-10-31
ME02901B (me) 2018-04-20
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
IL232797A0 (en) 2014-07-31
NZ625386A (en) 2017-03-31
SMT201700580T1 (it) 2018-01-11
CN104053673A (zh) 2014-09-17
MX376876B (es) 2025-03-07
MX353281B (es) 2018-01-08
US9988463B2 (en) 2018-06-05
GB201121513D0 (en) 2012-01-25
JP2015501830A (ja) 2015-01-19
PH12014501169B1 (en) 2014-09-08
US20210371543A1 (en) 2021-12-02
MY170980A (en) 2019-09-23
ZA201403836B (en) 2015-12-23
DK2791177T3 (en) 2017-12-18
CN104053673B (zh) 2018-01-12
AU2017268655A1 (en) 2017-12-21
NO2791177T3 (pt) 2018-02-03
PL2791177T3 (pl) 2018-03-30
SG11201402560WA (en) 2014-06-27
PH12014501169A1 (en) 2014-09-08
RU2017144629A (ru) 2019-02-18
US20180334511A1 (en) 2018-11-22
PE20190171A1 (es) 2019-02-01
ES2642718T3 (es) 2017-11-17
RU2642276C2 (ru) 2018-01-24
JP2018039798A (ja) 2018-03-15
AU2012351858A1 (en) 2014-06-12
WO2013088164A1 (en) 2013-06-20
IL232797B (en) 2018-07-31
SI2791177T1 (en) 2018-03-30
KR102114506B1 (ko) 2020-05-22
KR20140105556A (ko) 2014-09-01
EP2791177A1 (en) 2014-10-22
RS56510B1 (sr) 2018-02-28

Similar Documents

Publication Publication Date Title
BR112014014605A2 (pt) moléculas de anticorpo de ligação de trombina e usos das mesmas
MY162323A (en) Anticoagulant antidotes
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
HK1252862A1 (zh) 结合cd45的抗体分子
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
HK1243322A1 (zh) 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EA201490644A1 (ru) Терапевтические пептиды
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
WO2016014974A3 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
WO2016004389A3 (en) Monovalent binding proteins
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201291065A1 (ru) Антитела против vla-4
TN2013000388A1 (en) Anticoagulant antidotes
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
UA107836C2 (uk) Метод лікування хвороби альцгеймера
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
MX392341B (es) Métodos para mejorar la tolerancia gastrointestinal a productos alimenticios y bebidas, que comprenden carbohidratos dulces y de baja digestión.
UY36922A (es) Inhibidores de asgr
SG10201807066UA (en) Peptides and methods of use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: JANSSEN PHARMACEUTICALS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.